December can be an excellent time to begin SPRAVATO® treatment, particularly for individuals experiencing seasonal worsening of treatment-resistant depression. The rapid-acting nature of esketamine nasal spray, combined with structured treatment schedules that provide routine during chaotic holiday periods, often makes winter months strategically advantageous for starting this FDA-approved therapy.
Understanding SPRAVATO®’s unique treatment timeline helps patients and families make informed decisions about when to begin this innovative approach to treatment-resistant depression. Unlike traditional antidepressants that require weeks or months to show effects, SPRAVATO® often provides symptom relief within hours to days of initial treatment sessions.
The Science Behind SPRAVATO®’s Rapid Action
SPRAVATO® represents a fundamental breakthrough in depression treatment because it works through glutamate pathways rather than the serotonin systems targeted by conventional antidepressants. Mount Sinai researchers who contributed to esketamine’s development report that response rates typically range between 60-70% in treatment-resistant depression patients, with many experiencing rapid onset of symptom improvement (Mount Sinai Health System, 2019).
This rapid action occurs because esketamine blocks N-methyl-D-aspartate (NMDA) receptors, leading to increased production of brain-derived neurotrophic factor (BDNF) and enhanced neural plasticity. These changes can begin within hours of administration, though the full therapeutic benefits often develop over several treatment sessions.
Yale School of Medicine is currently conducting a landmark $12.6 million study comparing IV ketamine to esketamine nasal spray, recognizing the importance of understanding optimal treatment approaches for different patient populations (Yale School of Medicine, 2025). This ongoing research helps refine timing recommendations for beginning these innovative therapies.
At Oasis Therapeutics, Dr. PK Suchdev, Dr. James Mirazita, and Dr. Santharam Yadati bring decades of combined experience in managing treatment-resistant conditions. As New Hampshire Magazine’s 2025 Top Doctors, they understand how seasonal factors influence treatment decisions and work with patients to optimize timing for maximum therapeutic benefit.
December’s Advantages for Starting Treatment
The structured nature of SPRAVATO® treatment can provide beneficial routine during the potentially chaotic holiday season. Treatment sessions occur twice weekly initially, then weekly, creating consistent appointments that anchor wellness activities during a time when normal routines often get disrupted.
Many patients find that beginning SPRAVATO® in December allows them to establish treatment momentum before facing New Year pressures and winter’s deepest months. The rapid onset of action means patients might experience symptom improvement before major holiday gatherings, potentially enhancing their ability to engage meaningfully with family and friends.
December also typically offers better treatment center availability compared to busy periods earlier in the year. Many people postpone mental health treatments during summer months or busy fall schedules, making winter an optimal time for beginning intensive treatment programs that require regular appointments.
The holiday season’s slower work pace in many industries can make it easier to accommodate the required two-hour monitoring periods following each SPRAVATO® session. Patients must remain at certified treatment centers for observation after receiving the nasal spray, and reduced work pressures can make this scheduling more manageable.
Understanding the Treatment Structure
SPRAVATO® follows a specific FDA-approved treatment protocol that begins with an induction phase involving twice-weekly sessions for the first month. During this phase, patients typically receive treatments two times per week, typically with two to three days between sessions..
Each treatment session requires approximately three hours total: administration time, the two-hour monitoring period, and check-in procedures. Patients cannot drive after treatment sessions and must arrange transportation home, making treatment scheduling an important consideration for busy individuals.
The esketamine nasal spray itself takes only minutes to administer, but the comprehensive safety monitoring reflects the medication’s potent effects. Blood pressure monitoring, assessment for dissociation or sedation, and evaluation of overall response all occur during the observation period (PMC Academic Review, 2019).
Following the initial induction phase, treatment typically transitions to weekly sessions during the optimization phase, then potentially to every-two-week maintenance dosing. This gradual reduction in treatment frequency allows patients to assess their optimal maintenance schedule while building lasting symptom improvement.
Addressing Common December Concerns
Many patients worry about starting a new treatment during the holidays, fearing it might interfere with family plans or seasonal activities. However, SPRAVATO®’s rapid onset often means patients experience symptom improvement that actually enhances their holiday experience rather than detracting from it.
The cost of SPRAVATO® treatment concerns many families, particularly during expensive holiday seasons. Most major insurance plans cover FDA-approved esketamine treatment for qualified patients with treatment-resistant depression. Our team works closely with insurance providers to verify coverage and explore available options for making treatment accessible.
Some patients fear that beginning treatment in December means they’ll miss holiday celebrations due to side effects or scheduling conflicts. In reality, the structured treatment schedule often provides welcome routine during chaotic holiday periods, and many patients find their improved mood enhances their ability to participate in meaningful seasonal activities.
Holiday travel presents logistical considerations for SPRAVATO® patients, but treatment schedules can often be adjusted to accommodate important family visits or seasonal travel plans. Results vary by individual, but many patients successfully maintain treatment consistency while participating in holiday traditions.
Working with New England’s Winter Weather
New England’s winter weather requires special consideration for SPRAVATO® treatment scheduling. Our Nashua and Concord, New Hampshire locations are equipped to handle winter conditions, but patients should plan for potential weather-related schedule adjustments.
The two-hour observation period following each treatment provides a comfortable setting during harsh winter weather. Many patients appreciate having a warm, supervised environment where they can rest and recover while storms pass or roads are cleared.
Winter’s shortened daylight hours can complement SPRAVATO® treatment for patients also dealing with seasonal depression components. The structured indoor treatment schedule provides consistent light exposure and climate-controlled environments during months when outdoor activities become limited.
Optimizing Your December Treatment Experience
This week, patients considering SPRAVATO® can take several steps to prepare for potential December treatment initiation. First, contact your insurance provider to verify coverage for FDA-approved esketamine treatment and understand any pre-authorization requirements that might affect treatment start dates.
Second, arrange reliable transportation for treatment appointments, particularly important during winter months when driving after sessions is prohibited. This might involve coordinating with family members, friends, or professional transportation services that accommodate the approximately three-hour treatment window.
Third, communicate with family members about treatment schedules and monitoring requirements. Having supportive family understanding about appointment timing and post-treatment recovery periods helps create the optimal environment for successful treatment outcomes.
The holiday season doesn’t have to mean postponing treatment for depression that hasn’t responded to conventional approaches. December often provides unique advantages for beginning SPRAVATO® therapy, from schedule flexibility to rapid symptom improvement that can enhance holiday experiences. With proper planning and professional guidance, patients can use the winter months to establish treatment momentum that carries into the new year.
Starting SPRAVATO® in December positions patients to enter the new year with improved symptom management and established treatment routines. The combination of rapid-acting medication effects and structured treatment schedules can provide both immediate relief and long-term stability for individuals ready to address treatment-resistant depression with innovative approaches.
References
Mount Sinai Health System. (2019). Five things to know about esketamine. Physician’s Channel. https://physicians.mountsinai.org/news/five-things-to-know-about-esketamine
PMC Academic Review. (2019). Intranasal esketamine for use in treatment-resistant depression in conjunction with an oral antidepressant. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC6534172/
Yale School of Medicine. (2025, January 15). Yale-led study will compare effectiveness of IV ketamine and esketamine nasal spray. https://medicine.yale.edu/news-article/yale-led-study-will-compare-effectiveness-of-iv-ketamine-and-esketamine-nasal-spray/